ライフサイエンスコーパス: DLT

1 DLT (grade 3 neutropenia) was observed in 5 of 12 patien

2 DLT at the starting dose of 12 mg/m(2)/d resulted in de-

3 DLT caused by myelosuppression was seen in two of six pa

4 DLT criteria were revised to permit management of GI tox

5 DLT for HCC is feasible and achieves equivalent results

6 DLT in later courses included pleural effusions, hemangi

7 DLT is neurologic.

8 DLT occurred in 3 patients at 157 mg/m2, including nause

9 DLT occurred in one of six patients at 1,470 mg/m2 and t

10 DLT patients had more major complications (23.7% vs 13.0

11 DLT using livers from familial amyloidotic polyneuropath

12 DLT was defined as a 2-week delay in radiotherapy for gr

13 DLT was not observed with a fixed dose of 85 mg/m2 given

14 DLT was not observed.

15 DLT was observed in one of six patients at 300 mg (rash)

16 DLT was reached at level 3 (bevacizumab 5 mg/kg, FU 800

17 DLT was seen in six of 10 patients in the pancreatic stu

18 DLTs (grade 3 nausea, vomiting, fatigue in one; hyperten

19 DLTs (grade 4 neutropenia for > 5 days and grade 3 fatig

20 DLTs (grade 4 thrombocytopenia) was noted in two of the

21 DLTs (n = 40 total events) were principally fatigue (35%

22 DLTs at 431 mg/m(2) were grade 3 bilirubin (n = 1), AST

23 DLTs at 53 mg/m(2)/d for 3 days included hyperglycemia w

24 DLTs at doses above the 1.04-mg/m(2) MTD attributed to P

25 DLTs comprised elevated hepatic enzymes, hypophosphatemi

26 DLTs consisted of hypertensive crisis, congestive heart

27 DLTs include neuropathy, fatigue, and diarrhea.

28 DLTs included diarrhea (n = 1), mucositis (n = 1), and e

29 DLTs included grade 3 diarrhea (n = 1), prolonged grade

30 DLTs included hypercalcemia at 15 mg/m(2); hypophosphate

31 DLTs included reversible, asymptomatic T-wave inversions

32 DLTs observed with the combination of 13cRA and vorinost

33 DLTs occurred in two mild group patients (600 and 800 mg

34 DLTs were diarrhea, rash, and mucositis on the troxacita

35 DLTs were hepatic transaminitis, hyperbilirubinemia, and

36 DLTs were HFS, rash, and mucositis on the troxacitabine

37 DLTs were increased ALT/AST (n = 1), dizziness, confusio

38 DLTs were reported in five of six patients receiving OTX

39 DLTs were stomatitis and hand-foot syndrome.

40 DLTs were typhlitis, diarrhea, and mucositis, and the MT

41 Cohort 1 DLT included diarrhea and neutropenia.

42 With imatinib and docetaxel, cycle 1 DLT was found in three of 12 patients at docetaxel 30 mg

43 ients treated at this dose level had cycle 1 DLT.

44 MTD was defined at 0.8 mg/kg with 1 DLT observed (sepsis).

45 Among patients on schedule 1, DLT (grade 4 neutropenia complicated by fever and diarrh

46 ting toxicity (DLT), constituting four of 10 DLTs.

47 At doses higher than 2.4 mg/m(2), DLT granulocytopenia was observed.

48 romidepsin was safe, well tolerated, with 3 DLTs across all schedules (grade 3 oral mucositis x 2; g

49 8.2 yr) underwent HLT (n = 25), SLT (n = 3), DLT (n = 25), or repeat DLT (n = 3) and survived for mor

50 No grade 3 or 4 DLTs occurred in 108 infusions, and no patient had syste

51 Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycaemia in

52 A DLT and additional grade 2 toxicities made the 4,370-mg

53 Grade 4 hemorrhage, identified as a DLT, occurred in one patient in each of cohorts 2 and 3.

54 and the number still at risk of developing a DLT.

55 for toxicity in stratum I, one experienced a DLT (diarrhea) at 520 mg/m(2) twice daily, and all three

56 xceeded; two of three patients experienced a DLT (grade 3 sensory neuropathy and febrile neutropenia)

57 0 mg/m2/d, one of six patients experienced a DLT (headache), and this level was considered the maxima

58 g/m2/d, three of five patients experienced a DLT: grade 3 headache, grade 3 hypercalcemia, and grade

59 g was resumed at 400 mg, and four additional DLTs were observed: G4 neutropenia and G4 thrombocytopen

60 ced FAP disease but not before 6 years after DLT.

61 second part of the study defined the MTD and DLT in acute leukemia.

62 nitial part of the study defined the MTD and DLT in solid tumors.

63 observed earlier, which defined the MTD and DLT.

64 pants enrolled was 22 (range, 11 to 33), and DLTs occurring per study was three (range, 0 to 5).

65 th rash, diarrhea, and fatigue identified as DLTs.

66 reas all levels above the MTD had an average DLT rate of 36%.

67 The average DLT rate was 18%, which is lower than in previous report

68 ned-modality therapy was well tolerated, but DLT prevented OXP and 5-FU escalation.

69 ezomib dose exceeds the conventional ceiling DLT rate of 20% to 33%.

70 d diarrhea) appears to be the major combined DLT.

71 Diarrhea was the most common DLT.

72 ing schedules, with diarrhea the most common DLT.

73 The most common DLTs were neutropenia, stomatitis/pharyngitis, myalgia,

74 After adjusting for potential confounders, DLT and cadaveric LT had a similar 5-year survival rate

75 A relatively constant DLT rate at the 70, 90, and 115 mg/m2/dose levels result

76 The primary endpoint was first-cycle DLTs.

77 Doses were then adjusted to define DLT for each combination.

78 rs, dose-limiting toxicity (DLT) definition, DLT rate, patient-dose allocation, overdose, underdose,

79 nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events

80 Only one patient developed DLT (grade 3 diarrhea) at dosage level 5.

81 nly one heavily pretreated patient developed DLT (grade 4 neutropenia with fever and grade 3 diarrhea

82 At 3 mg/d, two of 19 patients developed DLT; one patient had grade 3 thrombocytopenia and grade

83 At 260 mg/m(2)/dose, DLTs occurred in two of six patients, both of whom exper

84 At higher doses, DLTs were observed using both dosing schedules, with dia

85 until the first dose-limiting toxic effect (DLT) and by 50% thereafter, in keeping with a 3+3 clinic

86 se levels of 60 mg/1,000 mg/m(2) experienced DLT.

87 level, only one of six patients experienced DLT (neutropenia > 7 days).

88 110 mg/m(2), two of six patients experienced DLT including grade 2 diarrhea and headache.

89 No re-treated patients experienced DLT.

90 eiving 1,150 mg/m(2) twice daily experienced DLTs (one each of rash, diarrhea, and fatigue).

91 uable for toxicity in stratum II experienced DLTs of rash at 900 mg/m(2) twice daily.

92 Two patients experienced DLTs (one each in the 80 mg and 600 mg dose groups).

93 cities were captured: 46% of patients' first DLTs and 88% of dose reductions or discontinuations of t

94 he *1/*28 genotype, the MTD was 700 mg (five DLTs per 22 patients), and 850 mg was not tolerated (fou

95 Four DLTs occurred in three of 40 DLT-evaluable patients (dia

96 the *1/*1 genotype, the MTD was 850 mg (four DLTs per 16 patients), and 1,000 mg was not tolerated (t

97 atients), and 850 mg was not tolerated (four DLTs per six patients).

98 ients were enrolled at 12 mg/m(2)/d; one had DLT (grade 3 diarrhea).

99 line phosphatase; three of five patients had DLT at 3,300 mg/m2: grade 3 AST/ALT (n = 1), grade 4 bil

100 In cohort 2, one of seven patients had DLT at 75 mg.

101 uated (70 mg/m(2)), zero of six patients had DLT.

102 At 17 mg/m(2)/d, two of four patients had DLTs (grade 3 nausea; intolerable grade 2 fatigue).

103 However, DLTs occurred at levels 2 and 1A.

104 contain a pentameric VIDLT ((V/I/L/F/Y)(V/I)DLT) core sequence that is also found in the SIMs in PIA

105 If DLT was hematologic, less-heavily pretreated patients we

106 chemoradiotherapy and gefitinib (cohort II), DLTs included one grade 4 diarrhea and one grade 4 neutr

107 The MTD was defined at 7.5 to 9 microg/kg; DLT included severe fatigue, neurotoxicity, liver functi

108 patocellular carcinoma (HCC) with Domino LT (DLT) using the "Double Piggy-back" technique.

109 The main DLT was peripheral neuropathy evident at the higher dose

110 totoxicity, and two had VOD, without meeting DLT criteria.

111 Most DLT occurred in patients with high PEG-IFN-lambda exposu

112 Two of nine DLTs were at the highest dose level.

113 No DLT occurred with 24-hour continuous infusion.

114 No DLT was encountered in cohort 3 with 12 patients at 150

115 No DLT was observed at 10 mg/m(2)/wk.

116 No DLT was recorded until 160 mg/day, when one patient had

117 th baseline neuropathy more than grade 1, no DLT occurred through 1.88 mg/kg (the phase II dose).

118 For patients with MM, no DLT was observed and MTD was not identified at up to 75

119 in cohorts of three to six patients when no DLT was identified.

120 No DLTs occurred at level 1.

121 No DLTs occurred in the three patients enrolled at 200 mg/m

122 No DLTs were observed in six patients in stratum one at sor

123 No DLTs were observed in the 1,500-mg cohort.

124 No DLTs were observed in the doses up to and including 80 m

125 No DLTs were observed up to the maximum proposed dose of 20

126 No DLTs were observed, and thus, the MTD was not estimated.

127 ne patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.

128 ar to historical controls, and there were no DLTs.

129 Treatment was well tolerated with no DLTs observed.

130 nd three more patients were enrolled with no DLTs.

131 000 mg per day in twice-daily dosing with no DLTs; however, plasma lapatinib concentrations plateaued

132 Non-DLT treatment-related adverse events occurring in more t

133 However, concomitant grade 1-2 non-DLT toxic effects (ie, gastrointestinal, fatigue, or cut

134 Non-DLTs included infusional reaction, rash, mucositis, prot

135 , GI, and hepatic toxicities were common non-DLTs.

136 The most frequent non-DLTs included diarrhea, rash, and hyperbilirubinemia.

137 ary end points included determination of non-DLTs and preliminary radiographic and pathologic respons

138 Other non-DLTs included ataxia and headache.

139 virtue of the fact that it possesses a novel DLT-containing KEAP1-interaction motif.

140 because of the relatively constant observed DLT rate at the lower four dose levels, the recommended

141 bility criteria, dose levels, definitions of DLT and MTD, and pharmacokinetic sampling times were des

142 Three of the five episodes of DLT developed at radiation doses < or = 36 Gy.

143 No episodes of DLT were observed at gemcitabine and capecitabine doses

144 /m(2), the estimated cumulative incidence of DLT was > 50%, and the estimated cumulative incidence of

145 60 to 100 mg/m(2) without the occurrence of DLT.

146 Two occurrences of DLT were observed.

147 The estimated probability of DLT for dose level 3 was .21 (90% posterior probability

148 was assessed as a function of the number of DLTs observed.

149 for the 3 + 3 design, whereas the number of DLTs per study was the same (average +/- SD, 3.3 +/- 1.1

150 One DLT of grade 3 elevation in ALT was seen.

151 At dose level 3 of 1000 mg/m(2), one DLT was encountered and three more patients were enrolle

152 he *28/*28 genotype, the MTD was 400 mg (one DLT per six patients), and 500 mg was not tolerated (thr

153 uncomplicated febrile neutropenia (the only DLT) in one patient, reversible elevations in hepatic tr

154 Other DLTs included diarrhea and fatigue; grade 3 thrombocytop

155 There were no other DLTs.

156 The primary DLT in both studies was diarrhea.

157 The primary DLTs were neutropenia and rash.

158 A high rate of acute and late mucosa-related DLT and a high rate of complete tumor response were obse

159 cute and late mucosal and pharyngeal-related DLT required de-escalation of gemcitabine dose in succes

160 = 25), SLT (n = 3), DLT (n = 25), or repeat DLT (n = 3) and survived for more than 72 h.

161 T), with at least two of three or two of six DLT at next higher dose.

162 g/m(2), respectively, met protocol-specified DLT criteria; however, at these doses 65% of successive

163 Ten DLTs occurred in nine patients, including grade 4 platel

164 The DLT of this DX-8951f schedule was granulocytopenia for m

165 The DLT was fatigue; 50 mg/d was the MTD.

166 The DLT was grade 3 pharyngolaryngeal dysesthesia, sensory n

167 The DLT was reversible hepatotoxicity and skin rash at 70 mg

168 The DLT was reversible hepatotoxicity at 55 mg/m(2).

169 The DLT was systemic, manifested as an elevation in liver fu

170 The DLT, MTD, PK, and adverse effect profile of oxaliplatin

171 sion; and 40 mg/m(2) for acute leukemia, the DLT being hepatotoxicity.

172 ith 3F8 10 mg/m(2)/d in prior protocols, the DLT of pain was defined as more than seven doses of opio

173 for 5 days: 2 mg/m(2) for solid tumors, the DLT being myelosuppression; and 40 mg/m(2) for acute leu

174 Prolonged neutropenia was the DLT at 420 mg/m(2) in heavily pretreated patients.

175 Grade 3, reversible ototoxicity was the DLT in less-heavily pretreated patients at 420 mg/m(2).

176 Myelosuppression was the DLT.

177 Diarrhea was the DLT.

178 The DLTs observed were one thrombosis (120 mg/m2), one grade

179 The DLTs were mainly myelosuppression and diarrhea.

180 The DLTs were thrombocytopenia and neutropenia.

181 The DLTs with both schedules were gastrointestinal.

182 rded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycaemia).

183 Stomatitis and hand-foot syndrome were the DLTs.

184 ted patients were to be enrolled until their DLTs were encountered, and MTDs defined.

185 In light of these DLTs and other toxicities noted at 120 mg, the dose of 8

186 In the expansion cohort at the MTD, three DLT's were encountered.

187 tients), and 500 mg was not tolerated (three DLTs per three patients).

188 Of those, 114 were submitted to DLT.

189 nd to describe the dose-limiting toxicities (DLT) and safety profile of this combination.

190 dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG)

191 erated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as

192 ermine the safety, dose-limiting toxicities (DLT), maximum-tolerated dose (MTD), and pharmacokinetics

193 nd to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib.

194 (MTD) and describe dose-limiting toxicities (DLTs) and the incidence and severity of other toxicities

195 The dose-limiting toxicities (DLTs) encountered were grade 3 diarrhea in three patient

196 Dose-limiting toxicities (DLTs) in the MONO study were fever, hypotension, acute l

197 Dose-limiting toxicities (DLTs) included perforated ulcer in one patient in the 50

198 d doses (MTDs) and dose-limiting toxicities (DLTs) of clofarabine, given as a 1-hour infusion daily f

199 e 60 mg/m(2), with dose-limiting toxicities (DLTs) of fatigue, nausea, vomiting, and diarrhea observe

200 cted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarub

201 Dose-limiting toxicities (DLTs) were assessed during cycle 1 of each cohort, and c

202 Dose-limiting toxicities (DLTs) were assessed during the first cycle to determine

203 ng a 3 + 3 design, dose-limiting toxicities (DLTs) were assessed weekly during cycle 1.

204 Dose-limiting toxicities (DLTs) were defined as treatment related, occurring durin

205 Dose-limiting toxicities (DLTs) were evaluated during the first 6 weeks of therapy

206 Dose-limiting toxicities (DLTs) were grade 3 hypersensitivity reaction (n = 1) and

207 No dose-limiting toxicities (DLTs) were observed at the 50, 65, and 85 mg/m(2) dose l

208 No dose-limiting toxicities (DLTs) were observed in patients treated in cohort I at e

209 erated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic and pharmacodynamic propertie

210 erated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic properties of pemetrexed in c

211 ose (MTD), safety, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of APR-246.

212 erated dose (MTD), dose-limiting toxicities (DLTs), and response with PEG IFN-alpha-2b.

213 y to determine the dose-limiting toxicities (DLTs), characterize the pharmacokinetic profile, and doc

214 d to determine the dose-limiting toxicities (DLTs), maximum tolerated dose, pharmacokinetic profile,

215 Dose-limiting toxicities (DLTs), MTD, and pharmacokinetics were determined for eac

216 rash, the primary dose-limiting toxicities (DLTs), occurred at 800 mg.

217 nd determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in c

218 toxicity profile, dose-limiting toxicities (DLTs), pharmacokinetics, and preliminary response rate f

219 tolerated without dose-limiting toxicities (DLTs).

220 ion and/or rash as dose-limiting toxicities (DLTs).

221 patients developed dose-limiting toxicities (DLTs): grade (G) 2 nausea at 120 mg; G3 fatigue at 250 m

222 ded determination of dose-limiting toxicity (DLT) and a phase II dose; secondary end points included

223 les to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to pro

224 mary end points were dose-limiting toxicity (DLT) and MTD.

225 e levels and was the dose-limiting toxicity (DLT) at 100 mg/m2/d of TMZ combined with 120 mg/m2/d O6B

226 Dose-limiting toxicity (DLT) consisted of elevation of both total and direct bil

227 Dose-limiting toxicity (DLT) consisted of worsening neuropathy at 1.34 mg/kg.

228 of four patients had dose-limiting toxicity (DLT) consisting of rash and hyperbilirubinemia, whereas

229 , design parameters, dose-limiting toxicity (DLT) definition, DLT rate, patient-dose allocation, over

230 reases were based on dose-limiting toxicity (DLT) encountered in cohorts of three consecutive patient

231 lead-in module, one dose-limiting toxicity (DLT) event was observed, while two (7%) of 28 had PSA de

232 sis syndrome was the dose-limiting toxicity (DLT) for CLL, the maximum-tolerated dose (MTD) was 75 mg

233 at was given without dose-limiting toxicity (DLT) from part 1 was administered continuously beginning

234 and those who had a dose-limiting toxicity (DLT) in cycle 1 irrespective of dose modification.

235 ermined based on the dose-limiting toxicity (DLT) in the first cycle.

236 primary endpoint was dose-limiting toxicity (DLT) in the first treatment cycle (21 days).

237 Dose-limiting toxicity (DLT) occurred in two of three patients treated at 33 mg/

238 atient cohorts until dose-limiting toxicity (DLT) occurred.

239 rated dose (MTD) and dose-limiting toxicity (DLT) of bevacizumab, when added to the standard FHX (flu

240 rated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vinc

241 rated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients with advanced solid tumor

242 daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular w

243 rated dose (MTD) and dose-limiting toxicity (DLT) of TAS-103 when administered on a weekly schedule t

244 rated dose (MTD) and dose-limiting toxicity (DLT) of UFT plus LV in this setting.

245 defined criteria for dose-limiting toxicity (DLT) or temporarily holding therapy with PEG-IFN-lambda.

246 doses with a 4-week dose-limiting toxicity (DLT) period.

247 Dose-limiting toxicity (DLT) seen in both cohorts at the starting dose required

248 evel associated with dose-limiting toxicity (DLT) through cycle 2 in < or = 20% of patients.

249 When dose-limiting toxicity (DLT) was consistently noted, patients then received 6 g

250 Treatment-related dose-limiting toxicity (DLT) was defined as any grade 3 or 4 nonhematologic toxi

251 Dose-limiting toxicity (DLT) was defined as any nonhematologic, treatment-relate

252 Dose-limiting toxicity (DLT) was defined as febrile neutropenia, prolonged neutr

253 Dose-limiting toxicity (DLT) was defined as grade 3 or worse GI/genitourinary (G

254 escalation until the dose-limiting toxicity (DLT) was defined.

255 30% to 35% until the dose-limiting toxicity (DLT) was defined.

256 No dose-limiting toxicity (DLT) was encountered on dose levels 1 and 2.

257 y 2 weeks' schedule, dose-limiting toxicity (DLT) was evident at the 1.75 and 1.9 mg/m2 dose levels,

258 Dose-limiting toxicity (DLT) was failure to reconstitute neutrophils to greater

259 Dose-limiting toxicity (DLT) was neurologic in both children and adults.

260 Dose-limiting toxicity (DLT) was observed at the third and fourth cohort (1 pati

261 aluable patients, no dose-limiting toxicity (DLT) was observed in patients treated at any dose level

262 No dose-limiting toxicity (DLT) was observed in the nine assessable patients who re

263 ued until consistent dose-limiting toxicity (DLT) was observed.

264 or until consistent dose-limiting toxicity (DLT) was observed.

265 Dose limiting toxicity (DLT) was seen at 20 mCi/m(2), with two patients experien

266 se elevation was the dose-limiting toxicity (DLT), and dose level 2 was the maximum tolerated dose (M

267 number experiencing dose-limiting toxicity (DLT), and the number still at risk of developing a DLT.

268 se level experienced dose-limiting toxicity (DLT), as did three of four at the 50-mg/m(2)/wk dose lev

269 primary endpoint was dose-limiting toxicity (DLT), assessed during the first treatment cycle (21 days

270 Dose-limiting toxicity (DLT), consisting of severe neutropenia with fever, sever

271 ug-related (93%) and dose-limiting toxicity (DLT), constituting four of 10 DLTs.

272 Dose-limiting toxicity (DLT), grade 4 neutropenia, occurred at 188 mg/m(2)/d x 5

273 in six patients had dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

274 Dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics, im

275 olerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), and adverse effect profile

276 olerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of

277 of six patients with dose-limiting toxicity (DLT), with at least two of three or two of six DLT at ne

278 study end point was dose-limiting toxicity (DLT).

279 s were evaluable for dose-limiting toxicity (DLT).

280 tcome was safety and dose-limiting toxicity (DLT).

281 /d in the absence of dose-limiting toxicity (DLT).

282 the use of a double-lumen endotracheal tube (DLT); a few centers use carbon dioxide (CO2) insufflatio

283 rs ago, confirmation of a double-lumen tube (DLT) position was limited to inspection and auscultation

284 00 mg (15 evaluable patients experienced two DLTs).

285 patients receiving VX-710 160 mg/m(2)/h, two DLTs were seen: reversible CNS toxicity and febrile neut

286 tients), and 1,000 mg was not tolerated (two DLTs per six patients).

287 Only patients undergoing DLT presented with piggy-back syndrome (7% vs 0%, P = 0.

288 ined, the dose of ZD9331 was increased until DLT occurred.

289 the more strict sequences consisting of (I/V)DLT that have a preference in high affinity SUMO2 and -3

290 d and tolerable at doses <or= 600 mg/d, were DLTs at 800 mg/d (maximum-tolerated dose).

291 , febrile neutropenia, and paresthesias were DLTs.

292 ior and no prior therapy, respectively, with DLT being neutropenia.

293 e curve for FU correlated significantly with DLT (P = .006) and grade 3 to 4 diarrhea (P = .004).

294 ZD1839 was well tolerated, with DLT observed at a dose well above that at which antitumo

295 0 mg once a day but none was tolerable, with DLTs of thrombocytopenia, gastrointestinal events (diarr

296 calation to 50 Gy has been completed without DLT.

297 evaluable for toxicity at 666 MBq/kg without DLT.

298 valuable at 444, 555, and 666 MBq/kg without DLT.

299 rmitted dose escalation to 160 mg/m2 without DLT.

300 Patients without DLT and no evidence of disease progression after 48 week

301 , and then six were treated at DL-2, without DLTs.